Abstract
The activity of trapidil, an antiaggregating agent with PDGF antagonist properties, was investigated in order to verify its possible modulating effect in the endothelial and platelet activation. PDGF, t-PA, PAI-1 and ET-1 plasma levels were measured before and after a 2 month treatment period with trapidil 200 mg tablets bid or placebo in 30 patients affected by POA in Fontaine stage II. PDGF and PAI-1 significantly (p < 0.05) increased in the placebo group, and PDGF also in the comparison between treatments (p < 0.05). Aggregation data demonstrate an absence of Ca++ antagonist action of trapidil. The results of this study suggest that trapidil can interfere with the combined vascular and platelet response in atherogenesis.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Arteriosclerosis / blood
-
Arteriosclerosis / drug therapy*
-
Blood Platelets / drug effects
-
Double-Blind Method
-
Endothelins / blood
-
Endothelium, Vascular / drug effects
-
Female
-
Humans
-
Male
-
Peripheral Vascular Diseases / blood
-
Peripheral Vascular Diseases / drug therapy*
-
Plasminogen Activator Inhibitor 1 / blood
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet-Derived Growth Factor / analysis
-
Tissue Plasminogen Activator / blood
-
Trapidil / therapeutic use*
Substances
-
Endothelins
-
Plasminogen Activator Inhibitor 1
-
Platelet Aggregation Inhibitors
-
Platelet-Derived Growth Factor
-
Tissue Plasminogen Activator
-
Trapidil